GLP-1 receptor (GLP-1R) agonists, such as liraglutide and exenatide, have demonstrated beneficial effects in both T2DM and PD, including enhancing dopamine midbrain function and promoting glucose-dependent secretion of insulin [133]. The gene discussed is INS; the disease is Parkinson disease.